Crucell to Webcast Presentation at UBS Warburg Global Life Sciences Conference
LEIDEN, Netherlands, Oct 3, 2002 - Dutch antibody and vaccine company Crucell N.V. (Nasdaq: CRXL; Euronext) announced today that it will present at the UBS Warburg Global Life Sciences Conference on Monday, October 7, 2002 at 2:30pm EDT. The conference is held at The Plaza in New York City, New York. Crucell's presentation will be webcast live for investors and available for replay following the conference. The webcast can be accessed by going to the UBS Warburg homepage at http://www.ubswarburg.com, clicking on UBS Warburg Conferences in the lower right hand corner and then following the link for Webcast under the Global Life Sciences Conference heading.
About Crucell
Crucell N.V. discovers and develops biopharmaceuticals that use the human immune system to combat cancer, infectious diseases and other conditions. Crucell leverages its patented technologies, MAbstract(TM), AdVac(TM), and PER.C6(TM), for discovery, development and production of antibodies and vaccines. Crucell offers its technologies to the pharmaceutical and biotechnology industry and also uses them to create its own product pipeline. Partners include Merck & Co. for the HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine and Centocor, a Johnson & Johnson company, for the CD46 antibody for treatment of various types of cancer. In addition, Crucell has over 20 licensees for its PER.C6(TM) technology. These include Novartis, GSK, Aventis and Schering AG. With headquarters in Leiden, The Netherlands, the company currently employs 200 people. Crucell is listed on Euronext and NASDAQ (ticker symbol CRXL). For more information visit http://www.crucell.com.
